Lifecore Biomedical, Inc. (NASDAQ: LFCR) is a Healthcare company (Drug Manufacturers - Specialty & Generic) with a market capitalization of $242M. The Maz Rating grades it against the other companies in its sector.
Lifecore Biomedical, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $6.39, Lifecore Biomedical, Inc. trades at 2.1x sales. Over the last twelve months it generated about $117M of revenue and a net loss of $72M. It runs a gross margin of 30.3%, an operating margin of -0.4% and a net margin of -57.7%. It shows return on equity of 381.6%, return on invested capital of -0.2% and a free cash flow yield of 2.1%. On the balance sheet: a debt-to-equity ratio of -3.04 and a current ratio of 3.84. Over the past 52 weeks the share price ranged from $3.63 to $8.98, with a beta of 0.99.
Lifecore Biomedical, Inc. does not currently pay a dividend.
8 Wall Street analyst ratings cover the stock: 4 Buy and 4 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Lifecore Biomedical, Inc. (LFCR) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 107.0% / 30% · (Cash+Inv) / Mkt Cap (36m) 11.0% / 30% · Interest income / Revenue 0.92% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 107.0% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 11.0% / 33% · Receivables / Mkt Cap (36m) 10.1% / 49% · Interest income / Revenue 0.92% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 107.0% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 11.0% / 33.33% · Receivables / Mkt Cap (24m) 10.1% / 33.33% · Interest income / Revenue 0.92% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 73.5% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 8.58% / 33.33% · Receivables / Avg Assets (4Q) 12.8% / 33.33% · Interest income / Revenue 0.92% / 5% | Fail |
| FTSE | Debt / Total Assets 97.7% / 33.33% · (Cash+ST Inv) / Total Assets 10.1% / 33.33% · (Cash+Recv) / Total Assets 19.3% / 33.33% · Interest income / Revenue 0.92% / 5% | Fail |
No. As of September 2026, Lifecore Biomedical, Inc. (LFCR) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Lifecore Biomedical, Inc. is over the AAOIFI limit on Debt / Mkt Cap (36m).
About 0.92% of each dividend: Lifecore Biomedical, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q1 2027). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.